This is a news story, published by Investor's Business Daily, that relates primarily to Elanco Animal Health news.
For more Elanco Animal Health news, you can click here:
more Elanco Animal Health newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Elanco Animal Health. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest eczema drug Zenrelia news, FDA news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Elanco stockInvestor's Business Daily
•70% Informative
Elanco Animal Health now expects approval for its new eczema drug Zenrelia to gain approval in the third quarter and for its parasiticide, Ceredelio Quattro , in the fourth quarter .
The company also expects the FDA to include a safety warning on the label for the drug.
Despite the delays, Elanco plans to deliver $600 million to $700 million in innovation sales by the end of 2025 .
VR Score
65
Informative language
67
Neutral language
25
Article tone
formal
Language
English
Language complexity
55
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links